Summary#
This bill, the Eliminating Thickets to Increase Competition (ETHIC) Act, limits how many patents a patent owner can assert in certain lawsuits tied to generic or biosimilar drug approval. It lets a patent owner assert no more than one patent from each defined “Patent Group” when suing a company that is seeking FDA approval or that makes or sells the approved product. The goal is to reduce large bundles of patents (“patent thickets”) that can delay competition from generics and biosimilars.
- Main change: In infringement suits that arise under the law used for FDA-related actions, a plaintiff may assert at most one patent per “Patent Group” against a given party.
- What counts as a Patent Group: Two or more commonly owned patents or applications that are linked by patent disclaimers used to avoid double patenting. (A disclaimer is a statement that a later patent will not extend the patenting period or claim the same invention as an earlier one.)
- Scope: The limit applies to suits against applicants for FDA approval of drugs or biosimilars, against holders of those approvals, and against parties making, selling, or importing those approved products.
- Timing: The limit applies to FDA approval or licensure applications filed on or after the bill’s enactment date.
- Procedure: A patent owner who asserts a patent from a Patent Group cannot later bring another suit asserting a different patent from that same Patent Group against the same party.
What it means for you#
- Patent holders (brand drug and biologic companies): You can still sue over patent infringement in these FDA-related cases, but you must pick at most one patent from each Patent Group to assert against a given applicant or maker. You cannot later bring a separate suit against that same party asserting another patent from the same group.
- Generic and biosimilar applicants (ANDA, 505(b)(2), and 351(k) filers): You may face fewer patents asserted against you in an FDA-linked infringement suit. This could lower legal risk and speed the ability to bring a product to market.
- Companies making, selling, or importing approved drugs/biologics: The same limit applies if you are sued under the listed legal provision; you may face fewer asserted patents from each commonly owned patent collection.
- Courts and litigants: Judges and parties will need to identify Patent Groups based on patent disclaimers. That will be part of case preparation and may require factual and legal determinations about ownership and disclaimers.
- Patients and purchasers: If the bill speeds generic or biosimilar entry, it could lead to earlier availability of lower-cost alternatives. This effect would depend on how often Patent Groups currently block competition.
Expenses#
No publicly available information.
- The bill text does not include a fiscal note or estimate.
- This change could shift legal costs: defendants might see lower litigation scope, while courts and parties may spend time and money resolving what patents belong to which Patent Group.
- There may be indirect business impacts for patent owners from reduced ability to assert multiple patents in related suits; the bill text does not quantify any revenue or budget effects.
Proponents' View#
- The bill appears intended to reduce “patent thickets” that bundle many patents to block competition.
- Supporters may argue that limiting asserted patents per Patent Group will make it harder to use large patent bundles to delay generic and biosimilar entry.
- This could be seen as improving competition for drugs and biologics and potentially lowering prices by making approval litigation simpler and narrower.
- The bill targets suits tied to FDA approval and licensure, so it focuses on the point where patent litigation can most directly delay market entry.
Opponents' View#
- One concern is that the bill limits patent enforcement rights by forcing patent owners to choose only one patent per Patent Group in certain suits.
- It is unclear how courts will apply the Patent Group definition in complex patent families, which could create disputes and added court work.
- The rule applies only to suits under the specific FDA-related legal provision; it does not stop patentees from asserting other patents in different kinds of suits, which may encourage strategic behavior.
- Patent owners might respond by changing how patents are owned or drafted to avoid being in the same Patent Group, creating new legal complexity.
- The bill does not provide a cost or savings estimate, so the net fiscal effect on government, industry, or consumers is not specified.